Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-904X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates ; volume:39 ; number:1 ; day:27 ; month:12 ; year:2021 ; pages:89-103 ; date:1.2022
Pharmaceutical research ; 39, Heft 1 (27.12.2021), 89-103, 1.2022
- Urheber
-
Aoyama, Michihiko
Tada, Minoru
Yokoo, Hidetomo
Demizu, Yosuke
Ishii-Watabe, Akiko
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11095-021-03158-x
- URN
-
urn:nbn:de:101:1-2022051722571946006288
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Aoyama, Michihiko
- Tada, Minoru
- Yokoo, Hidetomo
- Demizu, Yosuke
- Ishii-Watabe, Akiko
- SpringerLink (Online service)
Ähnliche Objekte (12)
The First FDA-Approved Antibody-Drug Conjugate
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Probing the Internalization and Efficacy of Antibody‐Drug Conjugate via Site‐Specific Fc‐Glycan Labelling of a Homogeneous Antibody Targeting SSEA‐4 Bearing Tumors
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
Internalization of CD239 highly expressed in breast cancer cells: a potential antigen for antibody-drug conjugates
An amino acid transporter subunit as an antibody–drug conjugate target in colorectal cancer
The First FDA-Approved Antibody-Drug Conjugate
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Probing the Internalization and Efficacy of Antibody‐Drug Conjugate via Site‐Specific Fc‐Glycan Labelling of a Homogeneous Antibody Targeting SSEA‐4 Bearing Tumors
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
Internalization of CD239 highly expressed in breast cancer cells: a potential antigen for antibody-drug conjugates
An amino acid transporter subunit as an antibody–drug conjugate target in colorectal cancer
The First FDA-Approved Antibody-Drug Conjugate
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Probing the Internalization and Efficacy of Antibody‐Drug Conjugate via Site‐Specific Fc‐Glycan Labelling of a Homogeneous Antibody Targeting SSEA‐4 Bearing Tumors
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
Internalization of CD239 highly expressed in breast cancer cells: a potential antigen for antibody-drug conjugates